ARQ 197 and Erlotinib

DRUG3 trials

Sponsors

Kyowa Kirin Co., Ltd.

Conditions

Advanced/Recurrent Non-small-cell Lung CancerNon-small-cell Lung Cancer

Phase 1

A Study of ARQ 197 in Combination With Erlotinib

CompletedNCT01069757

Kyowa Kirin Co., Ltd.Non-small-cell Lung Cancer

Start: 2010-02-28End: 2011-09-30Updated: 2017-03-15

A Study of ARQ 197 in Combination With Erlotinib

CompletedNCT01251796

Kyowa Kirin Co., Ltd.Advanced/Recurrent Non-small-cell Lung Cancer

Start: 2010-12-31End: 2012-11-30Updated: 2017-03-15

Phase 3

A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib

TerminatedNCT01377376

Kyowa Kirin Co., Ltd.Non-small-cell Lung Cancer

Start: 2011-07-31Updated: 2016-12-07

Related Papers

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).

2015-07-0798 citations

Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type <i>EGFR:</i> First report of a phase III ATTENTION trial.

Journal of Clinical Oncology2014-05-2015 citations